EA201000147A1 - Способ выделения и очистки монтелукаста - Google Patents

Способ выделения и очистки монтелукаста

Info

Publication number
EA201000147A1
EA201000147A1 EA201000147A EA201000147A EA201000147A1 EA 201000147 A1 EA201000147 A1 EA 201000147A1 EA 201000147 A EA201000147 A EA 201000147A EA 201000147 A EA201000147 A EA 201000147A EA 201000147 A1 EA201000147 A1 EA 201000147A1
Authority
EA
Eurasian Patent Office
Prior art keywords
montelukast
salts
formula
primary amines
isolation
Prior art date
Application number
EA201000147A
Other languages
English (en)
Other versions
EA018481B1 (ru
Inventor
Алес Галама
Йосеф Йирман
Гана Петрицкова
Original Assignee
Зентива, К.С.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Зентива, К.С. filed Critical Зентива, К.С.
Publication of EA201000147A1 publication Critical patent/EA201000147A1/ru
Publication of EA018481B1 publication Critical patent/EA018481B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Способ выделения монтелукаста формулы (I) из реакционных смесей, включающий преобразование сырого вещества в хорошо кристаллизующиеся соли с первичными аминами в среде по меньшей мере с одним органическим растворителем и ацетонитрилом с последующей перекристаллизацией этих солей с одновременным удалением химических примесей и использование химически чистых солей монтелукаста с первичными аминами для прямого преобразования в фармацевтически пригодную аморфную форму монтелукаста натрия формулы (II)
EA201000147A 2007-07-09 2008-07-08 Способ выделения аморфной соли монтелукаста натрия EA018481B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20070455A CZ302518B6 (cs) 2007-07-09 2007-07-09 Zpusob izolace a cištení montelukastu
PCT/CZ2008/000081 WO2009006861A2 (en) 2007-07-09 2008-07-08 A method for isolation and purification of montelukast

Publications (2)

Publication Number Publication Date
EA201000147A1 true EA201000147A1 (ru) 2010-06-30
EA018481B1 EA018481B1 (ru) 2013-08-30

Family

ID=40229131

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201000147A EA018481B1 (ru) 2007-07-09 2008-07-08 Способ выделения аморфной соли монтелукаста натрия

Country Status (6)

Country Link
US (1) US20100267958A1 (ru)
EP (1) EP2173718A2 (ru)
CZ (1) CZ302518B6 (ru)
EA (1) EA018481B1 (ru)
UA (1) UA100125C2 (ru)
WO (1) WO2009006861A2 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2287154A1 (en) 2009-07-14 2011-02-23 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast
WO2011121091A1 (en) 2010-03-31 2011-10-06 Krka, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
WO2012077133A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limited Processes for preparation of montelukast sodium and purification of diol intermediate
CN102060762B (zh) * 2011-01-28 2013-05-29 海南美大制药有限公司 孟鲁司特化合物及其新制法
JP6162004B2 (ja) * 2013-09-10 2017-07-12 株式会社トクヤマ モンテルカストナトリウム中間体の分析方法
JP6173864B2 (ja) * 2013-10-01 2017-08-02 株式会社トクヤマ モンテルカストナトリウムのアモルファスを製造する方法
CN104119270A (zh) * 2014-08-12 2014-10-29 牡丹江恒远药业有限公司 一种孟鲁司特钠的制备方法
CN105924392B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种孟鲁司特钠制备方法
CN105585524B (zh) * 2016-02-29 2018-03-02 山东新时代药业有限公司 一种由孟鲁司特酸制备孟鲁司特钠的方法
CN109503476A (zh) * 2018-12-26 2019-03-22 哈尔滨珍宝制药有限公司 一种孟鲁司特钠的合成工艺
CN112028824B (zh) * 2020-09-30 2021-12-14 山东安信制药有限公司 一种孟鲁司特钠的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW416948B (en) * 1993-12-28 2001-01-01 Merck & Co Inc Process for the preparation of leukotriene antagonists
US5937536A (en) * 1997-10-06 1999-08-17 Pharmacopeia, Inc. Rapid drying oven for providing rapid drying of multiple samples
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
CA2528228C (en) * 2003-06-06 2011-09-20 Morepen Laboratories Limited A method for the preparation of montelukast acid and sodium salt thereof in amorphous form
WO2005074935A1 (en) * 2004-01-30 2005-08-18 Teva Pharmaceutical Industries Ltd. Montelukast free acid polymorphs
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts
DE602005015174D1 (de) * 2004-04-21 2009-08-13 Teva Pharma Verfahren zur herstellung von montelukast-natrium
PL205637B1 (pl) * 2004-10-22 2010-05-31 Inst Farmaceutyczny Sposób wytwarzania kwasu (R,E)-(1-{1-{3-[2-(7-chlorochinolin-2-ylo)etenylo]fenylo}-3-[2-(1-hydroksy-1-metyloetylo)fenylo] propylosulfanylometylo}cyklopropylo)octowego i/lub jego farmaceutycznie dopuszczalnych soli
US7812168B2 (en) * 2005-07-05 2010-10-12 Teva Pharmaceutical Industries Ltd. Purification of montelukast
US20110092708A1 (en) * 2006-08-04 2011-04-21 Seeta Ramanjaneyulu Gorantla Process for the preparation of montelukast and its salts thereof
WO2008062478A2 (en) * 2006-11-20 2008-05-29 Manne Satyanarayana Reddy Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts

Also Published As

Publication number Publication date
CZ302518B6 (cs) 2011-06-29
US20100267958A1 (en) 2010-10-21
CZ2007455A3 (cs) 2009-03-04
WO2009006861A2 (en) 2009-01-15
EP2173718A2 (en) 2010-04-14
EA018481B1 (ru) 2013-08-30
UA100125C2 (ru) 2012-11-26
WO2009006861A3 (en) 2009-05-22

Similar Documents

Publication Publication Date Title
EA201000147A1 (ru) Способ выделения и очистки монтелукаста
CO6541539A2 (es) Procesos para preparar las formas cristalinas a y b de ilaprazol y proceso para convertir las formas cristalinas
AR098260A2 (es) Polimorfo cristalino de una sal de bisulfato de un antagonista del receptor de trombina, proceso para su preparación, composición y forma purificada
RU2018121834A (ru) Новое соединение бифенила или его соль
EA201270550A1 (ru) Процесс получения соединений для применения в качестве ингибиторов sglt2
NO20082263L (no) Organiske forbindelser
NO20091858L (no) Hydrobenzamid derivater som inhibitorer av HSP90
WO2011015522A3 (en) Process for the manufacture of pharmaceutically active compounds
BR112013011593A2 (pt) cristal de derivado de morfinan 7-carbamoíla-6,7-insaturada e método para produzir o mesmo
EA201291370A1 (ru) Способ получения плеуромутилинов
DOP2011000064A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il)metoxicarbonilaminio-metil] benzamida (ms-275)
NZ602872A (en) Crystalline peptide epoxyketone immunoproteasome inhibitor
AR078916A1 (es) Procedimiento para la purificacion de paliperidona
CL2010001639A1 (es) Proceso para preparacion del hemitartrato de [5-(4,6-dimetil-1h-benzoimidazol-2-il-metil-pirimidin-2-il]-[3-(metil-piperidin-4-il)propil]amina; proceso de recristalizacion del hemitartrato; y hemitaatrato cristalino de [5-(4,6-dimetil-1h-benzoimidazol-2-il)-4-metil- pirimidin-2-il]-[3-(1-metil-piperidin-4-il)-propil]-amina.
CO6700138A1 (es) Procedimiento de preparación de sal de l-arginina de perindoprilo
NO20075618L (no) Novel compounds as GLP-1 Agonists
MX2010009926A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexancarboxilico.
MX2010009876A (es) Nuevo proceso para la preparacion de derivados de acido ciclohexanocarboxilico por medio del derivado de ciclohexanocarboxamida correspondiente.
RU2009115852A (ru) Способ получения абакавира
NO20070776L (no) Forbedret prosess for fremstilling av mirtazapin
EA201290481A1 (ru) Способ получения гидрохлорида прасугреля в полиморфной форме в
MX2010007923A (es) Forma cristalina de abacavir que esta esencialmente libre de disolvente.
GEP20156350B (en) New process for synthesis of ivabradine and their additional salts with pharmaceutically acceptable acid
MX2010006218A (es) Compuestos organicos.
BR112017005454A2 (pt) composto de l-prolina do inibidor 2 do cotransportador de sódio-glicose, e mono-hidrato e cristal do composto de l-prolina

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU